Rita Laiginhas1, Jin Yang2, Philip J Rosenfeld2, Manuel Falcão3. 1. Department of Ophthalmology, CHEDV, Portugal; PDICSS, Faculty of Medicine of the University of Porto, Porto, Portugal. 2. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. 3. Department of Ophthalmology, Centro Hospitalar e Universitário de São João, Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal. Electronic address: falcao@med.up.pt.
Abstract
PURPOSE: To review the available literature on the prevalence, incidence, natural history, and exudative conversion rates of subclinical (treatment-naïve) nonexudative macular neovascularization (MNV) in patients with age-related macular degeneration (AMD). CLINICAL RELEVANCE: Nonexudative MNV is now known to be more prevalent in patients with AMD than initially thought and is bringing new insights into both the natural history and management of this very prevalent disease. METHODS: We conducted a literature search on PubMed, Scopus, and Web of Science, along with a manual search, from January 2014 to June 2019. We included studies that used optical coherence tomography angiography (OCTA) as a primary diagnostic tool to evaluate subclinical (treatment-naïve), nonexudative, neovascular AMD. RESULTS: Of the 258 screened articles, 12 were included. The prevalence of subclinical nonexudative neovascular AMD in the fellow eyes of patients with unilateral exudative AMD ranged from 6.25% to 27%. Although these lesions were not associated with a significant decrease in visual acuity, the presence of nonexudative MNV seems to be an important predictor of exudative disease. Incidence of exudation in the reviewed studies ranged from 20% to 80% (follow-up 6 months to 2 years). There is some evidence that nonexudative MNV may slow down the growth of adjacent geographic atrophy (GA). As long as exudation does not occur, it appears that subclinical nonexudative MNV is not responsible for the deterioration of visual function. CONCLUSIONS: Nonexudative MNV is an asymptomatic condition. Although nonexudative MNV seems to be a precursor for the formation of exudative neovascular AMD, there is evidence suggesting a protective effect in slowing the progression of GA. Early detection of nonexudative MNV before exudation develops should result in better monitoring of patients who are at high risk of conversion to exudative AMD. Though no controlled clinical trial has been performed to provide definitive recommendations, the authors of the studies included in this review agree that nonexudative lesions should not be treated until symptomatic exudation develops. Moreover, the existence of a nonexudative form of neovascular AMD would suggest that the term "neovascular AMD" should be preceded by either "exudative" or "nonexudative" when describing this neovascular stage of AMD.
PURPOSE: To review the available literature on the prevalence, incidence, natural history, and exudative conversion rates of subclinical (treatment-naïve) nonexudative macular neovascularization (MNV) in patients with age-related macular degeneration (AMD). CLINICAL RELEVANCE: Nonexudative MNV is now known to be more prevalent in patients with AMD than initially thought and is bringing new insights into both the natural history and management of this very prevalent disease. METHODS: We conducted a literature search on PubMed, Scopus, and Web of Science, along with a manual search, from January 2014 to June 2019. We included studies that used optical coherence tomography angiography (OCTA) as a primary diagnostic tool to evaluate subclinical (treatment-naïve), nonexudative, neovascular AMD. RESULTS: Of the 258 screened articles, 12 were included. The prevalence of subclinical nonexudative neovascular AMD in the fellow eyes of patients with unilateral exudative AMD ranged from 6.25% to 27%. Although these lesions were not associated with a significant decrease in visual acuity, the presence of nonexudative MNV seems to be an important predictor of exudative disease. Incidence of exudation in the reviewed studies ranged from 20% to 80% (follow-up 6 months to 2 years). There is some evidence that nonexudative MNV may slow down the growth of adjacent geographic atrophy (GA). As long as exudation does not occur, it appears that subclinical nonexudative MNV is not responsible for the deterioration of visual function. CONCLUSIONS: Nonexudative MNV is an asymptomatic condition. Although nonexudative MNV seems to be a precursor for the formation of exudative neovascular AMD, there is evidence suggesting a protective effect in slowing the progression of GA. Early detection of nonexudative MNV before exudation develops should result in better monitoring of patients who are at high risk of conversion to exudative AMD. Though no controlled clinical trial has been performed to provide definitive recommendations, the authors of the studies included in this review agree that nonexudative lesions should not be treated until symptomatic exudation develops. Moreover, the existence of a nonexudative form of neovascular AMD would suggest that the term "neovascular AMD" should be preceded by either "exudative" or "nonexudative" when describing this neovascular stage of AMD.
Authors: Jin Yang; Qinqin Zhang; Elie H Motulsky; Marie Thulliez; Yingying Shi; Cancan Lyu; Luis de Sisternes; Mary K Durbin; William Feuer; Ruikang K Wang; Giovanni Gregori; Philip J Rosenfeld Journal: Am J Ophthalmol Date: 2019-06-21 Impact factor: 5.258
Authors: Vittorio Capuano; Alexandra Miere; Lea Querques; Riccardo Sacconi; Adriano Carnevali; Francesca Amoroso; Francesco Bandello; Eric H Souied; Giuseppe Querques Journal: Am J Ophthalmol Date: 2017-07-20 Impact factor: 5.258
Authors: Luiz Roisman; Qinqin Zhang; Ruikang K Wang; Giovanni Gregori; Anqi Zhang; Chieh-Li Chen; Mary K Durbin; Lin An; Paul F Stetson; Gillian Robbins; Andrew Miller; Fang Zheng; Philip J Rosenfeld Journal: Ophthalmology Date: 2016-02-12 Impact factor: 12.079
Authors: Irene A Barbazetto; Namrata Saroj; Howard Shapiro; Pamela Wong; Allen C Ho; K Bailey Freund Journal: Am J Ophthalmol Date: 2010-04-08 Impact factor: 5.258
Authors: Qinqin Zhang; Anqi Zhang; Cecilia S Lee; Aaron Y Lee; Kasra A Rezaei; Luiz Roisman; Andrew Miller; Fang Zheng; Giovani Gregori; Mary K Durbin; Lin An; Paul F Stetson; Philip J Rosenfeld; Ruikang K Wang Journal: Ophthalmol Retina Date: 2017 Mar-Apr
Authors: P Hanutsaha; D R Guyer; L A Yannuzzi; A Naing; J S Slakter; J S Sorenson; R F Spaide; K B Freund; M Feinsod; D A Orlock Journal: Ophthalmology Date: 1998-09 Impact factor: 12.079
Authors: Alison D Treister; Peter L Nesper; Alaa E Fayed; Manjot K Gill; Rukhsana G Mirza; Amani A Fawzi Journal: Transl Vis Sci Technol Date: 2018-10-01 Impact factor: 3.283
Authors: Zhongdi Chu; Yingying Shi; Xiao Zhou; Liang Wang; Hao Zhou; Rita Laiginhas; Qinqin Zhang; Yuxuan Cheng; Mengxi Shen; Luis de Sisternes; Mary K Durbin; William Feuer; Giovanni Gregori; Philip J Rosenfeld; Ruikang K Wang Journal: Am J Ophthalmol Date: 2021-11-13 Impact factor: 5.258
Authors: Mengxi Shen; Qinqin Zhang; Jin Yang; Hao Zhou; Zhongdi Chu; Xiao Zhou; William Feuer; Xiaoshuang Jiang; Yingying Shi; Luis de Sisternes; Mary K Durbin; Ruikang K Wang; Giovanni Gregori; Philip J Rosenfeld Journal: Invest Ophthalmol Vis Sci Date: 2021-05-03 Impact factor: 4.799
Authors: Tiarnan D L Keenan; Elliott K Vanderford; Tharindu de Silva; Paul A Sieving; Catherine A Cukras Journal: Retina Date: 2021-11-01 Impact factor: 3.975
Authors: Amir H Kashani; Jane S Lebkowski; David R Hinton; Danhong Zhu; Mohamed A Faynus; Sanford Chen; Firas M Rahhal; Robert L Avery; Hani Salehi-Had; Clement Chan; Neal Palejwala; April Ingram; Wei Dang; Chih-Min Lin; Debbie Mitra; Juan Carlos Martinez-Camarillo; Jeff Bailey; Cassidy Arnold; Britney O Pennington; Narsing Rao; Lincoln V Johnson; Dennis O Clegg; Mark S Humayun Journal: Stem Cell Reports Date: 2022-02-03 Impact factor: 7.294